Drugs / EGFRBi-armed autologous activated T cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01081808 | Oct 2009 → Dec 2014 | metastatic malignant neoplasm | Roger Williams Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT00569296 | Nov 2007 → Dec 2014 | lung cancer | Roger Williams Medical Center | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFRBi-armed autologous activated T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00569296 ↗ |
| Action | Deplete | “Giving laboratory-treated autologous lymphocytes together with aldesleukin and GM-CSF may kill more tumor cells.” NCT01081808 ↗ |
| Modality | Cell therapy | “Activated T Cells (ATC) armed with the bispecific antibody OKT3 x Cetuximab (EGFRBi).” NCT01081808 ↗ |
| Route | Intravenous | “Patients receive EGFRBi-armed autologous ATCs IV over 30-60 minutes” NCT00569296 ↗ |
| Target | EGFR | “generation of EGFR-specific cytotoxic T-lymphocytes (CTL)” NCT00569296 ↗ |